Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 3/20 | 0.67 |
| ▸ | MGLL | Q99685 | 11/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113587 | 0.88 | KMT2A (0.71) | STSMGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL13591176 | 0.87 | STS (0.61) | STSMEN1KMT2A | |
| SCHEMBL14003525 | 0.87 | STS (0.61) | STSMEN1KMT2A | |
| SCHEMBL228921 | 0.86 | HSD11B1 (0.63) | MGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL4235957 | 0.86 | MGLL (0.56) | STSMGLLKMT2AHSD11B1 | |
| SCHEMBL24833605 | 0.86 | MGLL (0.56) | STSMGLLKMT2A | |
| SCHEMBL441012 | 0.86 | KDM4E (0.62) | STSMGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL3019433 | 0.86 | MEN1 (0.58) | STSMGLLMEN1KMT2A | |
| SCHEMBL5940516 | 0.86 | STS (0.57) | STSMEN1KMT2AHSD11B1 | |
| SCHEMBL4240126 | 0.85 | POLB (0.69) | STSMGLLMEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-03-09 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-111936503-A | Oxazin monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-18 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
| EP-0946511-B1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040171612-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2004-09-02 | — | — | US | disclosed |
| US-6693117-B2 | PIPERIDIN-4-YLIDENE DERIVATIVES | ASTRAZENECA CANADA INC. (CA) | 2004-02-17 | — | — | US | disclosed |
| US-20030149023-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2003-08-07 | — | — | US | disclosed |
| US-6455545-B2 | GASTROINTESTINAL DISORDERS | ASTRAZENECA CANADA INC. (CA) | 2002-09-24 | — | — | US | disclosed |
| US-20010021715-A1 | Novel compounds with analgesic effect | ASTRA PHARMA INC. | 2001-09-13 | — | — | US | disclosed |
| US-6187792-B1 | PIPERIDIN-4-METHYLIDENE-4-BENZAMIDE DERIVATIVES; OPOID RECEPTOR ANTAGONISTS; CANCER PAIN | ASTRA PHARMA INC. (CA) | 2001-02-13 | — | — | US | disclosed |
| EP-0946511-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028275-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | STS 388/4885MGLL 1/4885MEN1 1218/4885 |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | STS 2440/4885MGLL 3064/4885MEN1 86/4885 |
| US-20010021715-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | STS 4165/4885MGLL 1947/4885MEN1 4421/4885 |
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | STS 2440/4885MGLL 3064/4885MEN1 86/4885 |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | STS 2668/4885MGLL 3230/4885MEN1 92/4885 |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | STS 2668/4885MGLL 3230/4885MEN1 92/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | STS 388/4885MGLL 1/4885MEN1 1218/4885 |
| US-20030149023-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | STS 4165/4885MGLL 1947/4885MEN1 4421/4885 |
| US-20040171612-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | STS 4165/4885MGLL 1947/4885MEN1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.